AmCad BioMed Corporation (TPEX:4188)

Taiwan · Delayed Price · Currency is TWD

10.55

+0.10 (0.96%)

Jun 18, 2026, 1:30 PM CST

-35.87% (1Y)

Market Cap	668.16M -31.5%
Revenue (ttm)	30.04M -42.0%
Net Income	-53.66M
EPS	-0.85
Shares Out	63.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,332
Open	10.45
Previous Close	10.45
Day's Range	10.40 - 10.55
52-Week Range	10.20 - 17.20
Beta	0.29
Analysts	Hold
Price Target	n/a
Earnings Date	Aug 7, 2026

About AmCad BioMed

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company’s products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2008

Employees 34

Stock Exchange Taipei Exchange

Ticker Symbol 4188

Full Company Profile

Financial Performance

In 2025, AmCad BioMed's revenue was 30.44 million, a decrease of -42.69% compared to the previous year's 53.11 million. Losses were -55.72 million, 10.2% more than in 2024.

Financial Statements